Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 1978-1998

  Ge, Yiyu ^a   Kazi, Aslamuzzaman ^a   Marsilio, Frank ^a   Luo, Yunting ^a   Jain, Sanjula ^a   Brooks, Wesley ^a   Daniel, Kenyon G ^a   Guida, Wayne C ^a,b,c   Sebti, Saïd M ^a,b   Lawrence, Harshani R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; CHYMOTRYPSIN; N [3 (1H TETRAZOL 5 YLTHIO) 4 HYDROXYNAPHTHALEN 1 YL) 4' (TRIFLUOROMETHYL)BIPHENYL 4 SULFONAMIDE; N [3 (1H TETRAZOL 5 YLTHIO) 4 HYDROXYNAPHTHALEN 1 YL] 4 CYCLO HEXYLBENZENESULFONAMIDE; N [3 (1H TETRAZOL 5 YLTHIO) 4 HYDROXYNAPHTHALEN 1 YL] 4' FLUOROBIPHENYL 4 SULFONAMIDE; N [3 (1H TETRAZOL 5 YLTHIO) 4 HYDROXYNAPHTHALEN 1 YL] 5 PHENYL THIOPHENE 2 SULFONAMIDE; N [3 (1H TETRAZOL 5 YLTHIO) 4 HYDROXYNAPHTHALEN 1 YL]BIPHENYL 4 SULFONAMIDE; PI 8182; PROTEASOME INHIBITOR; THIOGLYCOLIC ACID; THIOPHENE; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHYMOTRYPSIN; DRUG STABILITY; HUMANS; NAPHTHOQUINONES; PROTEASOME ENDOPEPTIDASE COMPLEX; RABBITS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TETRAZOLES; THIOGLYCOLATES; THIOPHENES; TRIAZOLES;

EID: 84858010952     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201118h     Document Type: Article

References (39)

1. Pickart, C. M. Back to the future with ubiquitin Cell (Cambridge, MA, U.S.) 2004, 116, 181-190
2. Ciechanover, A. Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin proteasome system, and onto human diseases and drug targeting (Nobel lecture) Angew. Chem., Int. Ed. 2005, 44, 5944-5967
3. Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture) Angew. Chem., Int. Ed. Engl. 2005, 44, 5932-5943
4. Rose, I. Ubiquitin at fox chase Prix Nobel 2005, 218-225
5. Verdoes, M.; Florea, B. I.; van der Marel, G. A.; Overkleeft, H. S. Chemical Tools To Study the Proteasome Eur. J. Org. Chem. 2009, 3301-3313
6. Ciechanover, A.; Schwartz, A. L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2727-2730
7. Ciechanover, A.; Schwartz Alan, L. Ubiquitin-mediated degradation of cellular proteins in health and disease Hepatology 2002, 35, 3-6
8. King, R. W.; Deshaies, R. J.; Peters, J.-M.; Kirschner, M. W. How proteolysis drives the cell cycle Science 1996, 274, 1652-1658
9. Adams, J. The development of proteasome inhibitors as anticancer drugs Cancer Cell 2004, 5, 417-421
10. Rajkumar, S. V.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer J. Clin. Oncol. 2005, 23, 630-639
11. Chauhan, D.; Hideshima, T.; Anderson, K. C. Proteasome inhibition in multiple myeloma: therapeutic implication Annu. Rev. Pharmacol. Toxicol. 2005, 45, 465-476 2 plates.
12. Papandreou, C. N.; Daliani, D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S.-M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J. Clin. Oncol. 2004, 22, 2108-2121
13. Palombella, V. J.; Conner, E. M.; Fuseler, J. W.; Destree, A.; Davis, J. M.; Laroux, F. S.; Wolf, R. E.; Huang, J.; Brand, S.; Elliott, P. J.; Lazarus, D.; McCormack, T.; Parent, L.; Stein, R.; Adams, J.; Grisham, M. B. Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15671-15676
14. Wang, J.; Maldonado, M. A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases Cell. Mol. Immunol. 2006, 3, 255-261
15. Meng, L.; Kwok, B. H.; Sin, N.; Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function Cancer Res. 1999, 59, 2798-2801
16. Groll, M.; Kim, K. B.; Kairies, N.; Huber, R.; Crews, C. M. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of a′,b′-epoxyketone proteasome inhibitors J. Am. Chem. Soc. 2000, 122, 1237-1238
17. Groll, M.; McArthur Katherine, A.; Macherla Venkat, R.; Manam Rama, R.; Potts Barbara, C. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition J. Med. Chem. 2009, 52, 5420-5428
18. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 2001, 8, 739-758
19. Meiners, S.; Ludwig, A.; Stangl, V.; Stangl, K. Proteasome inhibitors: poisons and remedies Med. Res. Rev. 2008, 28, 309-327
20. Fuchs, O. Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma Mult. Myeloma 2009, 101-125
21. Lam, K. S.; Lloyd, G. K.; Neuteboom, S. T. C.; Palladino, M. A.; Sethna, K. M.; Spear, M. A.; Potts, B. C. From natural products to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent Nat. Prod. Chem. Drug Discovery 2010, 355-373
22. Zhou, H.-J.; Aujay Monette, A.; Bennett Mark, K.; Dajee, M.; Demo Susan, D.; Fang, Y.; Ho Mark, N.; Jiang, J.; Kirk Christopher, J.; Laidig Guy, J.; Lewis Evan, R.; Lu, Y.; Muchamuel, T.; Parlati, F.; Ring, E.; Shenk Kevin, D.; Shields, J.; Shwonek Peter, J.; Stanton, T.; Sun Congcong, M.; Sylvain, C.; Woo Tina, M.; Yang, J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 2009, 52, 3028-3038
23. Sterz, J.; von Metzler, I.; Hahne, J.-C.; Lamottke, B.; Rademacher, J.; Heider, U.; Terpos, E.; Sezer, O. The potential of proteasome inhibitors in cancer therapy Expert Opin. Invest. Drug 2008, 17, 879-895
24. Lawrence, H. R.; Kazi, A.; Luo, Y.; Kendig, R.; Ge, Y.; Jain, S.; Daniel, K.; Santiago, D.; Guida, W. C.; Sebti, S. M. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors Bioorg. Med. Chem. 2010, 18, 5576-5592
25. Kazi, A.; Lawrence, H.; Guida Wayne, C.; McLaughlin Mark, L.; Springett Gregory, M.; Berndt, N.; Yip Richard, M. L.; Sebti Said, M. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells Cell Cycle 2009, 8, 1940-1951
26. Avdeenko, A. P.; Velichko, N. V.; Romanenko, E. A.; Pirozhenko, V. V. Chlorination of N -arylsulfonyl-1,4-aminonaphthols and N -arylsulfonyl-1,4- naphthoquinone-1,4-imines Zh. Org. Khim. 1991, 27, 1747-1757
27. Altland, H. W.; Briffa, B. F., Jr. 1,4-Addition of triazolium thiolates to quinones J. Org. Chem. 1985, 50, 433-437
28. Avdeenko, A. P.; Evgrafova, N. I.; Ryazantsev, V. P.; Luk'yanenko, L. V.; Titov, E. V.; Velichko, N. V. Preparation of N -arylsulfonyl-2-chloro-1,4- naphthoquinone imines. USSR Patent 1558901, 86-4156772, 1558901, 19861204, 1990.
29. Avdeenko, A. P.; Evgrafova, N. I. Reaction of N -(arylsulfonyl)- p -naphthoquinonimines with acylhydrazines Zh. Org. Khim. 1987, 23, 1060-1063
30. Thiols; Coj, E.; Afanas'eva, G. B.; Chupakhin, O. N.; Sidorov, E. O. Reactions of benzo analogs of N -phenyl-1,4-benzoquinone monoimine with thiols Zh. Org. Khim. 1989, 25, 2409-2416
31. Fujita, S.; Sano, K. Reduction of quinones and quinonemonosulfonimides with N, N -diethylhydroxylamine J. Org. Chem. 1979, 44, 2647-2651
32. Lien, J.-C.; Huang, L.-J.; Teng, C.-M.; Wang, J.-P.; Kuo, S.-C. Synthesis of 2-alkoxy 1,4-naphthoquinone derivatives as antiplatelet, antiinflammatory, and antiallergic agents Chem. Pharm. Bull. 2002, 50, 672-674
33. Obafemi, C. A. Studies in the heterocyclic compounds. II. The mass spectra of some thiophene-sulfonyl derivatives Phosphorus Sulfur 1980, 8, 201-204
34. Matsubara, R.; Doko, T.; Uetake, R.; Kobayashi, S. Enesulfonamides as nucleophiles in catalytic asymmetric reactions Angew. Chem., Int. Ed. 2007, 46, 3047-3050
35. Adams, R.; Whitaker, L. Quinone imides. XXXIX. Adducts of quinone monoimides and conversion of active methylene adducts to benzofurans J. Am. Chem. Soc. 1956, 78, 658-663
36. 5 from oxone by simple and efficient methods Eur. J. Org. Chem. 2002, 3429-3434
37. Altland, H. W.; Briffa, B. F., Jr. 1,4-Addition of triazolium thiolates to quinones J. Org. Chem. 1985, 50, 433-437
38. Johnston, C. I. Angiotensin receptor antagonists: focus on losartan Lancet 1995, 346, 1403-1407
39. Patani, G. A.; LaVoie, E. J. Bioisosterism: A rational approach in drug design Chem. Rev. 1996, 96, 3147-3176